Literature DB >> 8323404

Beta haemolytic streptococci and musculoskeletal sepsis in adults.

C Deighton1.   

Abstract

Lancefield group A streptococci (GAS) account for 3-17% cases of septic arthritis, but other beta haemolytic streptococci (BHS) (groups B, C, and G) are being increasingly implicated. Epidemiological evidence suggests that the increase of BHS sepsis in adults is a true increase and not simply a reflection of better reporting. While underlying predisposing disease and old age are common concomitants of BHS sepsis, some subjects with devastating disease have been young and healthy. This is particularly the case for highly virulent M1 serotypes of GAS, where a toxic shock-like syndrome has led to a number of deaths in young adults in the United Kingdom and elsewhere. Musculoskeletal features, such as myalgias, painful swollen limbs, myositis, and fasciitis, are important features of this condition, so that rheumatologists may be involved in management. Group C and G musculoskeletal sepsis remains uncommon, with a high prevalence of underlying predisposing disease, or pre-existing arthritis in the septic joint. Group B BHS septic disease appears to be increasing in incidence. Musculoskeletal sepsis with these organisms usually takes place in subjects with other diseases, but healthy subjects have not been spared. Multiple septic foci and a rapidly destructive arthritis are not uncommon, and a recently described extra-articular feature is potentially blinding metastatic endophthalmitis. Clinicians need to be aware of an apparently increasing incidence of BHS musculoskeletal sepsis in adults so that early identification can lead to aggressive management in these potentially fatal infections.

Entities:  

Mesh:

Year:  1993        PMID: 8323404      PMCID: PMC1005078          DOI: 10.1136/ard.52.6.483

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  42 in total

Review 1.  Perinatal and neonatal infections: infections with group-B streptococci.

Authors:  M T Parker
Journal:  J Antimicrob Chemother       Date:  1979-05       Impact factor: 5.790

2.  Infective endocarditis: a changing disease. II.

Authors:  G W Hayward
Journal:  Br Med J       Date:  1973-06-30

3.  A study of HL-A antigen phenotype in rheumatic fever and rheumatic heart disease patients.

Authors:  J A Falk; J L Fleischman; J B Zabriskie; R E Falk
Journal:  Tissue Antigens       Date:  1973

4.  Bacterial (suppurative) arthritis in the adult.

Authors:  P J Kelly; W J Martin; M B Coventry
Journal:  J Bone Joint Surg Am       Date:  1970-12       Impact factor: 5.284

5.  Acute infectious agent arthritis (IAA): a detailed comparison of proved gonococcal and other blood-borne bacterial arthritis.

Authors:  A Garcia-Kutzbach; A T Masi
Journal:  J Rheumatol       Date:  1974-03       Impact factor: 4.666

6.  Infectious arthritis.

Authors:  J T Sharp; M D Lidsky; J Duffy; M W Duncan
Journal:  Arch Intern Med       Date:  1979-10

7.  Streptococci and aerococci associated with systemic infection in man.

Authors:  M T Parker; L C Ball
Journal:  J Med Microbiol       Date:  1976-08       Impact factor: 2.472

8.  Serious infection caused by group C streptococci.

Authors:  A T Ghoneim; E M Cooke
Journal:  J Clin Pathol       Date:  1980-02       Impact factor: 3.411

9.  Infections due to group C streptococci in man.

Authors:  D N Mohr; D J Feist; J A Washington; P E Hermans
Journal:  Am J Med       Date:  1979-03       Impact factor: 4.965

Review 10.  Pyomyositis in patients with diabetes mellitus.

Authors:  D M Walling; W G Kaelin
Journal:  Rev Infect Dis       Date:  1991 Sep-Oct
View more
  2 in total

1.  Toxic shock in children with bone and joint infections: a review of seven years of patients admitted to one intensive care unit.

Authors:  D L Kerr; E K Loraas; A C Links; T V Brogan; G A Schmale
Journal:  J Child Orthop       Date:  2017-10-01       Impact factor: 1.548

2.  Temporal trends of β-haemolytic streptococcal osteoarticular infections in western Norway.

Authors:  Oddvar Oppegaard; Steinar Skrede; Haima Mylvaganam; Bård Reiakvam Kittang
Journal:  BMC Infect Dis       Date:  2016-10-04       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.